Provenge Outcomes Data "Moderately" Strong For Labeled Use; Off-Label Insufficient, AHRQ Tech Assessment Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Clinical research demonstrating positive health outcomes from Dendreon's prostate cancer vaccine Provenge is "moderately" strong, the Agency for Healthcare Research and Quality concludes in a draft technology assessment prepared for the upcoming meeting of the Medicare Evidence Development and Coverage Advisory Committee.